Advanced Cancers Clinical Trial
Official title:
Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention
The goal of this research study is to learn how patients' think about constipation before and after receiving education about the subject.
If participant agrees to take part in the study, information about them (such as their age,
gender, ethnicity, religion, diagnosis, and drugs they are currently taking) will be
collected from their medical record.
Participant will also complete 1 questionnaire about constipation. It should take about 1-3
minutes to complete the questionnaire.
After completing the questionnaire, participant will be randomly assigned (as in the flip of
a coin) to 1 of 2 study groups. This is done because no one knows if one study group is
better, the same, or worse than the other group. Participant will have an equal chance of
being in either group.
- If participant is assigned to Group 1, they will watch a short educational video.
- If participant is assigned to Group 2, they will read a fact sheet.
Both the video and the fact sheet describe symptoms of constipation and the importance of
regular bowel movements. They should take about 3 minutes each to complete.
After participant has viewed the educational material, they will complete 3 questionnaires
about constipation and how helpful they think the video or fact sheet was in educating them
about constipation. It should take about 10 minutes total to complete these questionnaires.
Participant will watch the video/read the fact sheet and complete the questionnaires in their
room at the Supportive Care Clinic.
Length of Study:
Patient's participation on this study will be over after they have completed the last 3
questionnaires.
This is an investigational study.
Up to 200 participants will be enrolled in the study. All will take part at MD Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
| Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
| Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
| Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
| Terminated |
NCT00499382 -
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
|
N/A | |
| Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
| Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
| Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
| Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
| Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
| Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
| Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
| Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
| Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
| Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
| Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
| Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A |